Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Haematology & Bone Marrow Transplant
Haploidentical stem cell transplantation
What haploidentical stem cell transplantation is, how half-matched family donors provide stem cells, what clinical evidence shows for leukaemia and lymphoma, how the procedure compares with matched donor transplants, approximate costs in Turkey against the UK, US and Germany, post-transplant recovery milestones, infection and graft-versus-host risks, and how to assess an accredited bone marrow transplant centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Haematology & Bone Marrow Transplant
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Haploidentical Stem Cell Transplantation
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Haploidentical stem cell transplantation in Turkey: what it is and how it works
Haploidentical stem cell transplantation is an advanced form of allogeneic haematopoietic stem cell transplantation where the stem cell donor is a half-matched (haploidentical) biological relative, typically a parent, child, or sibling. In traditional allogeneic transplants, haematologists search for a full 10 out of 10 or 8 out of 8 human leukocyte antigen (HLA) match. A haploidentical donor shares exactly one HLA haplotype—amounting to a 5 out of 10 match—with the recipient. Because biological parents and children are invariably half-matches, and full siblings share a 50% likelihood of a half-match, almost every patient has an immediately available donor within their family. Accredited haematology centres perform haploidentical stem cell transplantation in Turkey for haematological malignancies and severe bone marrow failure when no fully matched donor can be identified in time.
Historically, half-matched transplants carried prohibitive risks of fatal graft rejection and severe graft-versus-host disease (GvHD). Over the past fifteen years, the widespread adoption of post-transplant cyclophosphamide protocols and selective T-cell depletion techniques has changed clinical outcomes, establishing haploidentical procedures as a reliable curative option worldwide. This guide outlines how the biological mechanism functions, what published survival data show, approximate costs in Turkey compared with the UK, US and Germany, key recovery milestones, and how to assess international transplant facilities. For an overview of comprehensive cancer care pathways, see our guide to oncology treatments in Turkey.
How does a half-matched donor stem cell transplant work?
The procedure follows a structured sequence of biological and clinical stages designed to replace diseased bone marrow with healthy donor stem cells while preventing immune conflict:
- Donor evaluation and stem cell collection: The half-matched donor undergoes extensive screening, including HLA typing, infectious disease testing, and general health clearance. Peripheral blood stem cells (PBSC) are mobilised using daily granulocyte colony-stimulating factor (G-CSF) injections for 4 to 5 days, followed by apheresis collection. Alternatively, bone marrow is harvested from the pelvic bone under general anaesthesia.
- Conditioning therapy: The patient enters a specialised isolation unit and receives conditioning chemotherapy, sometimes combined with low-dose total body irradiation (TBI), over 5 to 7 days. This conditioning clears residual cancer cells and suppresses the recipient's immune system so the donor cells can engraft without being rejected.
- Stem cell infusion (Day 0): The collected donor stem cells are infused into the patient's bloodstream through a central venous catheter, much like a regular blood transfusion. The cells naturally migrate through the bloodstream into the bone marrow cavities.
- Post-transplant cyclophosphamide (PTCy): On days +3 and +4 after the infusion, the patient receives high-dose cyclophosphamide. This medication selectively destroys rapidly dividing donor T-cells that would otherwise launch an attack against host tissues (acute GvHD), while sparing resting stem cells and protective regulatory immune cells.
- Engraftment and immune reconstitution: Immunosuppressive medications (tacrolimus or cyclosporine alongside mycophenolate mofetil) begin on day +5. Over the subsequent two to four weeks, the donor stem cells establish themselves in the marrow and begin producing new white blood cells, red blood cells, and platelets.
Does haploidentical stem cell transplantation work and what does evidence show?
Clinical evidence demonstrates that haploidentical stem cell transplantation provides effective, durable disease control for high-risk haematological disorders. Major international registry studies published by the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) confirm that when using modern post-transplant cyclophosphamide protocols, overall survival and leukaemia-free survival rates in patients transplanted during remission match those observed with matched unrelated donor (MUD) transplants.
The procedure works particularly well for acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), myelodysplastic syndromes (MDS), and advanced lymphomas. A key therapeutic mechanism is the graft-versus-leukaemia (GvL) effect, in which the donor's immune cells recognise and eliminate residual microscopic cancer cells that survived intensive chemotherapy. However, published evidence is clear about the boundaries of the procedure: patients with active, uncontrolled, or chemorefractory leukaemia at the time of transplant experience significantly higher relapse rates. Non-relapse mortality from opportunistic viral and fungal infections remains a serious clinical factor that requires experienced intensive management.
Haploidentical stem cell transplantation cost in Turkey compared with the UK, US and Germany
The ranges below provide approximate commercial estimates for complete haploidentical stem cell transplant programmes across major medical destinations. Bone marrow transplantation is an intensive, inpatient medical discipline involving extended isolation, advanced cellular processing, and dedicated laboratory support. Final quotes are confirmed individually by each hospital following comprehensive case evaluation.
| Country | Approximate cost range |
|---|---|
| Turkey | €40,000 – €85,000 |
| United Kingdom | €100,000 – €220,000 |
| United States | €250,000 – €600,000 |
| Germany | €90,000 – €200,000 |
Several clinical variables influence the total haploidentical stem cell transplantation price. The choice between peripheral blood apheresis and operating theatre bone marrow harvesting alters collection costs. Myeloablative conditioning requires longer hospitalisation and more supportive care than reduced-intensity regimens. The duration of inpatient isolation—typically 4 to 8 weeks—forms a substantial portion of the cost, as do blood transfusions, daily laboratory panels, and antimicrobial therapies. A comprehensive package standardly includes pre-transplant donor and recipient assessments, conditioning chemotherapy, cell processing, isolation room accommodation, medical and nursing care, and early post-discharge outpatient check-ups.
To understand the patient coordination process and hospital arrangements, read how it works before travelling. You can request an initial assessment through our free quote service to receive a hospital estimate.
Who is a candidate for haploidentical transplantation, and who is not?
Determining transplant eligibility requires a multidisciplinary haematology board review evaluating disease status, physical fitness, and donor suitability.
Typical candidates include:
- Adults and children with high-risk or relapsed acute leukaemia, myelodysplastic syndrome, severe aplastic anaemia, or refractory lymphoma who lack an HLA-matched sibling.
- Patients who have achieved morphological complete remission or a low burden of disease following induction or salvage chemotherapy.
- Individuals with adequate organ reserve, confirmed by cardiac echocardiography (adequate left ventricular ejection fraction), pulmonary function testing (adequate carbon monoxide diffusing capacity), and normal liver and kidney markers.
- Patients with a motivated, medically fit first-degree relative willing to donate stem cells.
The procedure is generally not recommended for:
- Patients with chemorefractory, rapidly proliferating leukaemia with high blast percentages at the time of planned conditioning.
- Individuals with severe, irreversible heart, pulmonary, or liver failure, or end-stage renal disease.
- Patients with active, uncontrolled systemic fungal, bacterial, or viral infections.
- Recipients with high titres of donor-specific anti-HLA antibodies (DSA) directed against the selected donor, which cause severe primary graft failure unless successfully desensitised.
The transplantation process: conditioning, infusion and engraftment
The inpatient transplant pathway is organised around "Day 0", the day stem cells are infused:
- Admission and central access (Days -10 to -8): The patient is admitted to a specialised positive-pressure, HEPA-filtered isolation room. A dual- or triple-lumen central venous catheter (such as a Hickman line) is inserted into a major vein under local anaesthesia to administer medications and draw blood samples without repeated needle punctures.
- Conditioning regimen (Days -7 to -2): High-dose chemotherapy agents (such as fludarabine, busulfan, or cyclophosphamide) are administered intravenously according to established protocol guidelines. Total body irradiation may be incorporated for selected leukaemia types. This phase eliminates residual disease and clears space in the bone marrow.
- Rest day (Day -1): A medication-free interval allows the patient's body to clear the conditioning chemotherapy so it does not damage the incoming donor cells.
- Stem cell infusion (Day 0): The collected donor cells are brought to the bedside and infused through the central line over one to two hours. The patient remains awake in bed while vital signs are tracked continuously by nursing staff.
- Immunosuppressive modulation (Days +3 to +5): Post-transplant cyclophosphamide is given on days +3 and +4, accompanied by protective bladder infusions (mesna) and vigorous hydration. Routine immunosuppressants begin on day +5.
- Nadir and engraftment (Days +7 to +21): Blood counts drop to near-zero levels. Supportive transfusions of irradiated platelets and red cells are administered as needed. Once the donor cells multiply, the absolute neutrophil count rises above 500 cells per microlitre for three consecutive days, signalling successful engraftment.
What are realistic clinical outcomes and what does recovery mean?
In allogeneic stem cell transplantation, "before and after" assessments do not reflect cosmetic visual transformations. Instead, outcomes are measured by haematological recovery, bone marrow clearance, and donor cell engraftment. Reputable transplant centres do not present aesthetic photographs; they provide objective clinical milestones based on laboratory data.
Before the transplant, patients often carry residual disease burden, compromised blood counts, and toxicities from preceding chemotherapy courses. Following conditioning and transplant, patients experience temporary hair loss, profound fatigue, mucosal inflammation, and diminished appetite. As donor cells take over haematopoiesis, normal marrow architecture is re-established. Complete donor chimerism—meaning that all bone marrow and peripheral blood cells originate from the donor—is assessed via molecular testing at day +30, day +60, and day +100. Hair begins regrowing within three to six months, stamina improves gradually, and blood counts stabilise to normal levels over the first year.
Recovery milestones and post-transplant isolation
Planning haploidentical stem cell transplantation recovery requires understanding the extended timeline involved in rebuilding an immune system from donor cells:
- Weeks 1 to 4 (Inpatient isolation): The patient remains in a positive-pressure room with strict dietary and visitor precautions. Staff wear protective gear to prevent opportunistic infections while blood counts are at their lowest.
- Weeks 5 to 8 (Early outpatient transition): Following stable engraftment and independence from daily transfusions, the patient is discharged to outpatient accommodation situated close to the hospital in Turkey. Clinic visits occur two to three times weekly for blood counts, electrolyte management, and physical assessment.
- Day +100 milestone: Between months 2 and 3, a comprehensive reassessment is performed, including a bone marrow aspirate, cytogenetic analysis, chimerism quantification, and organ function tests. International patients who are clinically stable, infection-free, and showing full donor chimerism can typically be cleared to return home around this time, usually after an 80 to 100 day stay.
- Months 4 to 12 (Immune maturation): Immunosuppressive medications are tapered gradually under the direction of haematology specialists. Patients follow strict hygiene guidelines, avoid crowded enclosed environments, and begin a scheduled programme of post-transplant revaccinations around month 12.
Risks, graft-versus-host disease and complications
Haploidentical stem cell transplantation is an intensive curative procedure accompanied by documented risks. Evidence published by the NHS, the European Society for Blood and Marrow Transplantation (EBMT), and the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) highlights the key clinical concerns:
- Graft-versus-host disease (GvHD): Acute GvHD occurs when donor T-cells attack recipient tissues, primarily the skin (maculopapular rash), liver (elevated bilirubin and jaundice), and gastrointestinal tract (watery diarrhoea and abdominal cramping). Grade II to IV acute GvHD affects roughly 25% to 35% of haploidentical recipients treated with post-transplant cyclophosphamide. Chronic GvHD may develop after day +100, causing scleroderma-like skin changes, dry eyes, oral mucosal sensitivity, or joint stiffness.
- Opportunistic infections: During the neutropenic period and subsequent months of T-cell immune deficiency, patients face significant risks of bacterial bloodstream infections, invasive fungal pneumonia (such as Aspergillus), and viral reactivations. Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK polyomavirus are common challenges monitored by weekly quantitative viral PCR blood tests.
- Primary graft failure: In approximately 3% to 8% of cases, the donor stem cells fail to engraft, leaving the bone marrow aplastic. This risk is notably elevated if donor-specific anti-HLA antibodies were present prior to conditioning.
- Organ toxicities: High-dose conditioning drugs can trigger hepatic sinusoidal obstruction syndrome (veno-occlusive disease), acute kidney injury, or haemorrhagic cystitis. Experienced transplant units use prophylactic medications to reduce these risks.
- Disease recurrence: Relapse of the underlying malignancy remains the primary cause of late treatment failure, reinforcing the necessity of achieving maximum disease remission before undertaking transplantation.
Choosing a transplant centre in Turkey and essential questions to ask
When selecting a haematology centre for haploidentical transplantation in Turkey, clinical accreditation and infrastructure must take precedence over promotional marketing. Look for hospitals holding JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) accreditation or formal licensing from the Turkish Ministry of Health for allogeneic haematopoietic stem cell transplantation. Verify that the facility features dedicated positive-pressure isolation wards with continuous HEPA air filtration, an on-site apheresis unit, cryopreservation laboratories, 24-hour haematology intensive care capabilities, and an established team of transplant haematologists, infectious disease specialists, and specialised nurses.
Red flags include clinics that cannot provide JACIE documentation, teams that do not routinely test for donor-specific antibodies (DSA), facilities lacking negative- and positive-pressure isolation rooms, or any representative promising certain remission without reviewing cytogenetic and disease remission data.
Essential questions to ask your clinical coordinator:
- Is your bone marrow transplant unit JACIE-accredited, and how many haploidentical transplants does the team conduct annually?
- Which specific conditioning regimen and GvHD prophylaxis protocol do you plan to use for my diagnosis?
- What screening protocols do you carry out on the family donor, including anti-donor HLA antibody testing?
- What infection-control measures, air-filtration standards, and viral PCR surveillance programmes are active in the unit?
- How many weeks of inpatient care are budgeted, and how frequently will I be examined after hospital discharge?
- What emergency and intensive care facilities are immediately available on site if complications arise?
- What is included in the package fee, and what financial contingencies exist if extended ICU treatment or additional cell collections become necessary?
You can review our step-by-step guidance on how it works to understand medical records review and airport coordination. To begin a confidential medical review with a haematology team, visit our free quote page.
Hospitals with Oncology in Turkey
Frequently asked questions
Haploidentical stem cell transplantation is an allogeneic transplant using healthy blood-forming stem cells from a half-matched biological family member, such as a parent, child, or sibling. Modern protocols use post-transplant cyclophosphamide chemotherapy to remove alloreactive immune cells, allowing half-matched family members to serve as effective donors when no fully matched donor is available.
Yes. Extensive clinical data from international haematology registries show that haploidentical transplantation with post-transplant cyclophosphamide achieves survival and remission rates comparable to matched unrelated donor transplants in acute leukaemia and lymphoma. Success depends on achieving remission before transplantation, patient organ function, and managing infection and graft-versus-host risks during immune recovery.
Haploidentical stem cell transplantation in Turkey typically costs between €40,000 and €85,000, compared with €100,000 to €220,000 in the UK and up to €600,000 in the US. The price covers donor and recipient testing, conditioning chemotherapy, isolation room stay, cell processing, and early outpatient care. Each hospital provides a formal written quote.
In stem cell transplantation, before-and-after results refer to clinical remission, donor chimerism, and normalising blood counts rather than cosmetic appearance. Patients experience profound fatigue, hair loss, and mucositis during conditioning, followed by gradual cellular recovery, hair regrowth, and energy improvement over six to twelve months as donor cells establish a healthy immune system.
Initial recovery requires four to six weeks in a hospital isolation room until white blood cells and platelets engraft. Outpatient monitoring in Turkey continues for another two to three months. Full immune system reconstitution takes twelve to twenty-four months, requiring strict hygiene, prophylactic medications, and revaccination as the new immune system matures.
The stem cell infusion itself causes no pain and is administered through a central line, similar to a blood transfusion. However, conditioning chemotherapy causes uncomfortable side effects, particularly painful mouth ulcers (mucositis), nausea, and fatigue. Transplant teams provide round-the-clock supportive care, including patient-controlled analgesia, antiemetics, and mucosal mouthwashes to manage discomfort effectively.
A successful stem cell transplant can provide lifelong curative remission for haematological cancers and marrow failure. The donor immune cells permanently replace the recipient's diseased bone marrow and mount a continuing graft-versus-leukaemia effect against residual cancer cells. Long-term surveillance remains necessary because disease relapse or late immune complications can occasionally arise.
Haploidentical transplantation is an intensive procedure carrying significant risks of graft-versus-host disease, viral reactivation, and bacterial infections. Modern post-transplant cyclophosphamide protocols have dramatically reduced severe complications, bringing safety profiles close to matched donor transplants. Treatment in a JACIE-accredited centre with experienced haematologists and HEPA-filtered isolation facilities is critical for patient safety.
Matched unrelated donors require extensive international registry searches that often take two to four months, which can risk disease progression. Haploidentical family donors are readily available within days and are strongly motivated. Clinical trials show similar overall survival and relapse rates between the two approaches when modern immunosuppressive protocols are used.
Patients typically stay in Turkey for 80 to 100 days. This includes pre-transplant donor and recipient workup, four to six weeks of inpatient isolation until donor cell engraftment, and six to eight weeks of outpatient monitoring near the hospital to manage medications, check chimerism, and treat potential early complications.
Patient stories